Table 4 Haematologic toxicities

From: A phase I/II trial of irinotecan–cisplatin combined with an anti-late-diarrhoeal programme to evaluate the safety and antitumour response of this combination therapy in patients with advanced non-small-cell lung cancer

  

Number of patients (cycles) with toxicity

  

Leukopenia

Neutropenia

Anemia

Thrombocytopenia

Dose level

No. Pts a (cycles)

Mean nadir (Range: μ l−1)

Grade 2

Grade 3

Grade 4

Mean nadir (Range: μ l−1)

Grade 2

Grade 3

Grade 4

Mean nadir (Range: g dl−1)

Grade 3–4

Mean nadir (Range: × 104 μ l−1)

Grade 3–4

Phase I

60N

7 (13)

2806 (1000–4160)

3 (5)

3 (3)

0

1276 (324–2288)

2 (5)

1 (2)

2 (2)

10.7 (8.0–12.7)

0

18.3 (11.3–25.1)

0

60P

5 (8)

2123 (1300–3560)

3 (4)

1 (3)

0

877 (312–1940)

1 (1)

2 (5)

1 (1)

9.8 (8.7–13.3)

0

14.8 (8.0–18.8)

0

65P

5 (14)

3055 (2100–4700)

4 (8)

0

0

1204 (483–1998)

2 (3)

2 (6)

1 (1)

10.7 (8.5–13.5)

0

15.9 (9.4–26.8)

0

70P

4 (9)

3167 (2000–4050)

1 (1)

0

0

1367 (860–1789)

1 (4)

3 (3)

0

11.4 (9.5–13.7)

0

23.4 (16.9–35.6)

0

75P

6 (15)

2825 (1800–4080)

4 (9)

1 (1)

0

1303 (378–2489)

3 (4)

2 (5)

1 (1)

9.8 (8.0–12.1)

0

20.6 (8.7–33.6)

0

80P

2 (2)

1235 (400–2070)

1 (1)

0

1 (1)

446 (200–691)

0

1 (1)

1 (1)

11.7 (10.8–12.5)

0

12.6 (9.4–15.8)

0

Phase II

48 (140)

2926 (510–7290)

21 (64)

15 (22)

1 (2)

1303 (112–3612)

11 (49)

24 (42)

7 (10)

9.8 (5.7–13.6)

9 (14)

19.2 (4.9–45.5)

1 (1)

  1. aNumber of patients (cycles).
Back to article page